BR0107445A - Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco - Google Patents

Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco

Info

Publication number
BR0107445A
BR0107445A BR0107445-8A BR0107445A BR0107445A BR 0107445 A BR0107445 A BR 0107445A BR 0107445 A BR0107445 A BR 0107445A BR 0107445 A BR0107445 A BR 0107445A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
vial
syringe
preparation
fulvestrant
Prior art date
Application number
BR0107445-8A
Other languages
English (en)
Other versions
BR0107445B1 (pt
Inventor
John Raymond Evans
Rosalind Ursula Grundy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0107445(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0107445A publication Critical patent/BR0107445A/pt
Publication of BR0107445B1 publication Critical patent/BR0107445B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçãO FARMACêUTICA, USO DE FULVESTRANTE NA PREPARAçãO DE UMA FORMULAçãO FARMACêUTICA, E, SERINGA OU FRASCO". A invenção refere-se a uma nova formulação farmacêutica de liberação sustentada, adaptada para a administração por injeção, que contém o composto 7<244>-[9(4,4,5,5,5-pentafluoropentilsulfinil)nonil]estra-1,3,5 (10)-trieno-3,17<225>-diol, mais particularmente a uma formulação, adaptada para a administração por injeção, que contém o composto 7<244>-[9(4,4,5,5,5-pentafluoropentilsulfinil)nonil]estra-1,3,5 (10)-trieno-3,17<225>-diol, em uma solução em um veículo de ricinoleato, que compreende adicionalmente pelo menos um álcool e um solvente de éster não-aquoso, que é miscível no veículo de ricinoleato.
BRPI0107445-8A 2000-01-10 2001-01-08 formulação farmacêutica, e, uso de fulvestrante na preparação de uma formulação farmacêutica. BR0107445B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0000313.7 2000-01-10
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
GB0008837.7 2000-04-12
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation

Publications (2)

Publication Number Publication Date
BR0107445A true BR0107445A (pt) 2002-09-17
BR0107445B1 BR0107445B1 (pt) 2012-10-30

Family

ID=26243352

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0107445-8A BR0107445B1 (pt) 2000-01-10 2001-01-08 formulação farmacêutica, e, uso de fulvestrante na preparação de uma formulação farmacêutica.

Country Status (41)

Country Link
US (5) US20030125387A1 (pt)
EP (4) EP1669073A3 (pt)
JP (3) JP3713237B2 (pt)
KR (1) KR100802366B1 (pt)
CN (1) CN1222292C (pt)
AR (1) AR027510A1 (pt)
AT (1) ATE306928T1 (pt)
AU (1) AU762080B2 (pt)
BE (1) BE1013477A3 (pt)
BG (1) BG65776B1 (pt)
BR (1) BR0107445B1 (pt)
CA (1) CA2351004C (pt)
CH (1) CH696260A5 (pt)
CO (1) CO5280206A1 (pt)
CY (1) CY1116520T1 (pt)
CZ (1) CZ304689B6 (pt)
DE (2) DE60114145T3 (pt)
DK (2) DK2266573T3 (pt)
EE (1) EE05421B1 (pt)
EG (1) EG24074A (pt)
ES (3) ES2248272T5 (pt)
FR (1) FR2803516B1 (pt)
GB (3) GB0000313D0 (pt)
HK (3) HK1049286B (pt)
HU (1) HU230162B1 (pt)
IL (2) IL150230A0 (pt)
IS (1) IS2932B (pt)
IT (2) ITTO20010005A1 (pt)
MX (1) MXPA02006698A (pt)
MY (1) MY118583A (pt)
NL (1) NL1017075C2 (pt)
NO (2) NO336286B1 (pt)
PL (1) PL202525B1 (pt)
PT (2) PT2266573E (pt)
RU (1) RU2263507C9 (pt)
SI (2) SI1250138T2 (pt)
SK (1) SK287221B6 (pt)
TW (1) TWI259086B (pt)
UA (1) UA75879C2 (pt)
WO (1) WO2001051056A1 (pt)
ZA (1) ZA200204165B (pt)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
CA2453111A1 (en) * 2001-07-07 2003-01-23 Alan Marshall Irving Pharmaceutical formulation for the intramuscular administration of fulvestrant
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
BRPI0608777A2 (pt) * 2005-04-15 2010-01-26 Schering Corp métodos para tratamento ou prevenção de cáncer, bem como uso de inibidores de igf1r na preparação de composições farmacêuticas
JP2009509942A (ja) * 2005-09-26 2009-03-12 ホスピラ・オーストラリア・ピーティーワイ・リミテッド フルベストラント製剤
KR20100121505A (ko) * 2008-03-07 2010-11-17 싸이도우스 엘엘씨. 플배스트랜 제제
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
PT2616078T (pt) 2010-09-16 2020-03-31 Shimoda Biotech Pty Ltd Composições de fulvestrant e métodos de uso
CA2836831C (en) * 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
WO2013153559A1 (en) * 2012-04-09 2013-10-17 Scidose, Llc Fulvestrant formulations
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2014169462A1 (zh) 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
US20160213682A1 (en) * 2013-09-06 2016-07-28 Salah Uddin Ahmed Fulvestrant compositions
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
EP3116497A2 (en) 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US9980947B2 (en) 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3912680A1 (en) 2015-10-01 2021-11-24 Olema Pharmaceuticals, Inc. Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
JP2018530597A (ja) 2015-10-13 2018-10-18 テミス メディケア リミティド フルベストラント組成物
CN108699024B (zh) 2015-12-09 2022-03-11 伊利诺伊大学评议会 苯并噻吩基选择性雌激素受体下调剂化合物
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
JP6682163B2 (ja) * 2016-04-06 2020-04-15 富士フイルム株式会社 医薬組成物
US9969732B2 (en) 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
WO2017193048A1 (en) * 2016-05-06 2017-11-09 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
JP6611932B2 (ja) * 2016-05-31 2019-11-27 富士フイルム株式会社 医薬組成物
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
CN109311876B (zh) * 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
WO2017216280A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
SG11202002105WA (en) 2017-09-11 2020-04-29 Atossa Therapeutics Inc Methods for making and using endoxifen
JP7220712B2 (ja) 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
BR112020008888A2 (pt) 2017-11-16 2020-10-20 Novartis Ag terapias de combinação
CN111465398A (zh) * 2018-01-31 2020-07-28 富士胶片株式会社 注射用制剂的制造方法
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
EP3801553A4 (en) 2018-05-24 2022-04-27 Kashiv Biosciences, LLC PRODRUGS OF FULVESTRANT
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
KR20210118812A (ko) 2018-11-01 2021-10-01 사이로스 파마수티컬스, 인크. 시클린-의존성 키나제 7 (cdk7)의 억제제
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113329792A (zh) 2019-02-15 2021-08-31 诺华股份有限公司 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CA3136088A1 (en) 2019-05-20 2020-11-26 Matthew T. Burger Mcl-1 inhibitor antibody-drug conjugates and methods of use
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
CN113260353A (zh) * 2019-12-11 2021-08-13 上海博志研新药物技术有限公司 氟维司群药物组合物、其制备方法及应用
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2021388021A1 (en) 2020-11-24 2023-06-22 Novartis Ag Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
CA3202759A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP4288434A1 (en) 2021-02-02 2023-12-13 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023121232A1 (ko) * 2021-12-20 2023-06-29 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) † 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (pt) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
KR980008226A (ko) 1996-07-05 1998-04-30 다케다 쿠니오 시각기능장애의 예방 및 치료제
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
NZ504783A (en) 1997-12-03 2002-12-20 Merck & Co Inc Long acting injectable formulations containing hydrogenated castor oil
CA2366787C (en) 1999-04-01 2013-03-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
CA2453111A1 (en) 2001-07-07 2003-01-23 Alan Marshall Irving Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
EE05421B1 (et) 2011-06-15
HK1049286B (zh) 2006-04-07
HK1052884A1 (en) 2003-10-03
EP1250138B1 (en) 2005-10-19
UA75879C2 (en) 2006-06-15
PL202525B1 (pl) 2009-07-31
PT102548A (pt) 2001-07-31
RU2263507C9 (ru) 2020-03-18
NO20023227D0 (no) 2002-07-03
FR2803516B1 (fr) 2003-03-28
JP2003519659A (ja) 2003-06-24
NO336286B1 (no) 2015-07-13
EP1669073A3 (en) 2008-03-19
AU2386301A (en) 2001-07-24
CH696260A5 (de) 2007-03-15
US8329680B2 (en) 2012-12-11
CZ304689B6 (cs) 2014-09-03
RU2002121507A (ru) 2004-03-20
NL1017075A1 (nl) 2001-07-11
TWI259086B (en) 2006-08-01
CZ20022384A3 (cs) 2002-09-11
IL150230A0 (en) 2002-12-01
EP1669073A2 (en) 2006-06-14
CY1116520T1 (el) 2017-03-15
NO20023227L (no) 2002-07-03
BG106833A (en) 2003-03-31
US20030125387A1 (en) 2003-07-03
US20120329766A1 (en) 2012-12-27
NO337329B1 (no) 2016-03-14
BE1013477A3 (fr) 2002-02-05
PL356030A1 (en) 2004-06-14
US20100152149A1 (en) 2010-06-17
US8466139B2 (en) 2013-06-18
ES2248272T5 (es) 2015-08-19
ES2186517A1 (es) 2003-05-01
NL1017075C2 (nl) 2001-09-25
CA2351004C (en) 2003-02-18
GB0008837D0 (en) 2000-05-31
AR027510A1 (es) 2003-04-02
HUP0204137A2 (hu) 2003-04-28
JP3713237B2 (ja) 2005-11-09
AU762080B2 (en) 2003-06-19
DE60114145T3 (de) 2015-09-17
ES2543384T3 (es) 2015-08-18
DK1250138T4 (en) 2015-07-27
SK287221B6 (sk) 2010-03-08
US20050043285A1 (en) 2005-02-24
JP2004107353A (ja) 2004-04-08
EP1250138A1 (en) 2002-10-23
BR0107445B1 (pt) 2012-10-30
US20010020016A1 (en) 2001-09-06
CA2351004A1 (en) 2001-07-10
GB0000313D0 (en) 2000-03-01
CO5280206A1 (es) 2003-05-30
MXPA02006698A (es) 2002-09-30
PT2266573E (pt) 2015-07-28
WO2001051056A1 (en) 2001-07-19
DK2266573T3 (en) 2015-07-20
ITTO20010005A0 (it) 2001-01-09
ITTO20010008A0 (it) 2001-01-10
ZA200204165B (en) 2003-10-29
GB0100407D0 (en) 2001-02-21
ITTO20010008A1 (it) 2002-07-10
SK9842002A3 (en) 2003-05-02
SI1250138T2 (sl) 2015-09-30
ES2186517B2 (es) 2004-03-16
US6774122B2 (en) 2004-08-10
CN1222292C (zh) 2005-10-12
ES2248272T3 (es) 2006-03-16
NO20150741L (no) 2002-07-03
FR2803516A1 (fr) 2001-07-13
EP2286818A1 (en) 2011-02-23
KR20020073499A (ko) 2002-09-26
EP2266573B1 (en) 2015-06-17
SI2266573T1 (sl) 2015-08-31
IS2932B (is) 2015-12-15
EG24074A (en) 2008-05-11
ATE306928T1 (de) 2005-11-15
US7456160B2 (en) 2008-11-25
IS6454A (is) 2002-07-03
DE60114145T2 (de) 2006-07-13
MY118583A (en) 2004-12-31
DK1250138T3 (da) 2006-01-23
RU2263507C2 (ru) 2005-11-10
GB2359254B (en) 2002-06-19
SI1250138T1 (sl) 2006-02-28
DE60114145D1 (de) 2006-03-02
EP2286818B1 (en) 2020-03-18
EP2266573A1 (en) 2010-12-29
HU230162B1 (hu) 2015-09-28
EP1250138B2 (en) 2015-07-08
GB2359254A (en) 2001-08-22
HK1150021A1 (en) 2011-10-28
KR100802366B1 (ko) 2008-02-13
EE200200387A (et) 2003-10-15
CN1394141A (zh) 2003-01-29
BG65776B1 (bg) 2009-11-30
JP2011190275A (ja) 2011-09-29
IL150230A (en) 2006-10-31
HK1049286A1 (en) 2003-05-09
HUP0204137A3 (en) 2005-03-29
HK1052884B (zh) 2006-07-14
ITTO20010005A1 (it) 2001-07-11
DE10100779A1 (de) 2001-07-26

Similar Documents

Publication Publication Date Title
BR0107445A (pt) Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco
BR9916829A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol
BR9810729A (pt) Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante
BR0210898A (pt) Formulação farmacêutica, dose unitária da mesma, uso de pulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco estéril
BR9814729A (pt) Método e composição de uma preparação oral de itraconazol
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
BR0110981A (pt) Emulsão com baixo teor de água
PE20020968A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
BR0110141A (pt) Melhorias em ou relacionando-se a formulações para uso em dispositivos inaladores
BR9911070A (pt) Sistema de liberação de droga compreendendo uma matéria-prima de medicamento sólido acentuadamente compacto
BR9907832A (pt) Composição de propofol contendo sulfito
AR019262A1 (es) Proceso para la preparacion de una formulacion que comprende una sustancia activa o sustancias activas asociadas con un portador, y formulacion preparadapor dicho proceso.
CY1107142T1 (el) Τυποποιηση που περιλαμβανει fulvestrant
AR033688A1 (es) Composicion parenteral reconstituible
BR9911344A (pt) Composto, undecanoato de ment, uso do mesmo, formulação farmacêutica, e, kit para a contracepção masculina.
AP2002002674A0 (en) Clear Aqueous Anaesthetic composition.
BR0115952A (pt) Composição de emulsão para administração terapêutica, método de administração, processo para o preparo de uma formulação contendo derivados de fosfato de agentes de transferência de elétrons
SV2002000301A (es) Composicion farmaceutica ref. z-1032
PA8633801A1 (es) Derivados de sulfamoilbenzoato y sulfamoilaminobenzoato de estriol, y derivados de sulfamoilbenzoato y sulfamoilaminobenzoato de estetrol
BRPI0414524A (pt) misturas de agente tenso-ativo/solvente
BR9904552A (pt) Processo para a preparação de unidades de dosagem farmacêuticas, granulado, e, embalagem
BR0108455A (pt) Composição cosmética de uma fase, transparente
BR0109312A (pt) Processo para a preparação de formulações de liberação acelerada utilizando fluidos comprimidos
BR0109139A (pt) Composições farmacêuticas incluindo alginatos
BR0011100A (pt) Formulação lìquida de ditiocarbamato essencialmente anidra, e, uso da mesma

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ATRAVES DA PETICAO INPI/RJ NO 038290, DE 16/06/2002, O REQUERENTE SOLICITOU O EXAME DO PRESENTE PEDIDO E EFETUOU A RETRIBUICAO EQUIVALENTE A 32 REIVINDICACOES. NO ENTANTO, NO ATO DO DEPOSITO, FOI APRESENTADO UM NOVO QUADRO REIVINDICATORIO CONSTANDO 33 REIVINDICACOES. DESSE MODO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO O REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO REFERENTE A 1 REIVINDICACAO QUE EXCEDE AS 31 PAGAS.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/10/2012, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.034124/2013-11 ORIGEM: JUIZO DA 01A TURMA ESPECIALIZADA EM MATERIA PENAL E PREVIDENCIARIA DO TRF 2A REGIAO/RJ PROCESSO NO 0102889-09.2013.4.02.5101 ACAO ORDINARIA DE NULIDADE DA PATENTE AUTOR: EUROFARMA LABORATORIOS S/A REU: ASTRAZENECA AB, AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: EUROFARMA LABORATORIOS S. A.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.034124/13 SECAO JUDICIARIA DO RIO DE JANEIRO - 31A VARA FEDERAL PROCESSO NO. 2013.51.01.102889-4 AUTOR: EUROFARMA LABORATORIOS LTDA REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI, ASTRAZENECA AB E AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA DECISAO: " COM FUNDAMENTO NO 2O DO ARTIGO 56 DA LEI 9.279/96 - DEFIRO A ANTECIPACAO DE TUTELA, PARA SUSPENDER OS EFEITOS DA PATENTE DE INVENCAO PI0107445-8, RESTRITIVAMENTE AS PARTES DA PRESENTE DEMANDA. DEFIRO A INCLUSAO DA ABIFINA (ASSOCIACAO BRASILEIRA DAS INDUSTRIAS DE QUIMICA FINA, BIOTECNOLOGIA E SUAS ESPECIALIDADES) COMO AMICUS CURIAE."

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.034124/13 SECAO JUDICIARIA DO RIO DE JANEIRO - 31A VARA FEDERAL PROCESSO NO. 2013.51.01.102889-4 AGRAVO DE INSTRUMENTO NO 2013.02.01.017410-4 AGRAVANTE: ASTRAZENECA AB AGRAVADO: EUROFARMA LABORATORIOS LTDA DECISAO: "ANTE O EXPOSTO, DEFIRO A ANTECIPACAO DA TUTELA PARA O FIM DE DETERMINAR A SUSPENSAO DO PROCESSO ADMINISTRATIVO DE NULIDADE DE PATENTE DE INVENCAO PI 0107445-8 INSTAURADO PELA EMPRESA-AGRAVADA, EUROFARMA LABORATORIOS S/A, ATE O JULGAMENTO DO PRESENTE RECURSO."

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.137885/14 SECAO JUDICIARIA DO RIO DE JANEIRO - 31A VARA FEDERAL PROCESSO NO 2013.51.01.102889-4 AGRAVO DE INSTRUMENTO NO 2013.02.01.015134-7 AGRAVANTE: ASTRAZENECA AB AGRAVADO(S): EUROFARMA LABORATORIOS LTDA E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: ANTE O EXPOSTO, DOU PROVIMENTO PARCIAL AO PRESENTE AGRAVO DE INSTRUMENTO TAO SOMENTE PARA REVOGAR A ANTECIPACAO DA TUTELA, MANTENDO-SE EM VIGENCIA A PATENTE PI0107445-8, DE TITULARIDADE DA AGRAVANTE, ATE A PROLACAO DA SENTENCA NO PROCESSO ORIGINARIO, DE NO 2013.51.01.102889-4, MOMENTO NO QUAL O MAGISTRADO PODERA REAPRECIAR A QUESTAO.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.034124/2013- SECAO JUDICIARIA DO RIO DE JANEIRO 13A VARA FEDERAL PROCESSO NO 0102889-09.2013.4.02.5101 AUTOR: EUROFARMA LABORATORIOS LTDA REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL- INPI, ASTRAZENECA AB E VIGILANCIA SANITARIA -ANVISA DECISAO: DEFIRO ANTECIPACAO DE TUTELA REQUERIDA PARA DETERMINAR A SUSPENSAO DOS EFEITOS DA PATENTE PI0107445-8, COM EFEITOS ERGA OMNES.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.034124/2013-11 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO PROCESSO: NO0102889-09.2013.4.02.5101 AUTOR: EUROFARMA LABORATORIOS S/A REU: ASTRAZENECA AB (ASTRAZENECA), INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E AGENCIA NACIONAL DE VIGILANCIA SANITARIA ? ANVISA DECISAO: INFORMO QUE TRANSITOU EM JULGADO EM 05/10/2018.

B16D Grant of patent or certificate of addition of invention cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 16.1 NA RPI NO 2182 DE 30/10/2012 CONFORME INPI-52400.034124/2013-11 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO PROCESSO: NO 0102889-09.2013.4.02.5101